|A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable|
A Cortellini, M Bersanelli, S Buti, K Cannita, D Santini, F Perrone, R Giusti, ...
Journal for immunotherapy of cancer 7 (1), 1-11, 2019
|The psychophysiology primer: a guide to methods and a broad review with a focus on human–computer interaction|
B Cowley, M Filetti, K Lukander, J Torniainen, A Henelius, L Ahonen, ...
Foundations and Trends® in Human–Computer Interaction 9 (3-4), 151-308, 2016
|Clinical outcomes of patients with advanced cancer and pre‐existing autoimmune diseases treated with anti‐programmed death‐1 immunotherapy: a real‐world transverse study|
A Cortellini, S Buti, D Santini, F Perrone, R Giusti, M Tiseo, M Bersanelli, ...
The oncologist 24 (6), e327-e337, 2019
|Correlations between the immune-related adverse events spectrum and efficacy of anti-PD1 immunotherapy in NSCLC patients|
A Cortellini, R Chiari, B Ricciuti, G Metro, F Perrone, M Tiseo, M Bersanelli, ...
Clinical lung cancer 20 (4), 237-247. e1, 2019
|Integrated analysis of concomitant medications and oncological outcomes from PD-1/PD-L1 checkpoint inhibitors in clinical practice|
A Cortellini, M Tucci, V Adamo, LS Stucci, A Russo, ET Tanda, ...
Journal for immunotherapy of cancer 8 (2), 2020
|KEAP1-driven co-mutations in lung adenocarcinoma unresponsive to immunotherapy despite high tumor mutational burden|
D Marinelli, M Mazzotta, S Scalera, I Terrenato, F Sperati, L D'Ambrosio, ...
Annals of Oncology 31 (12), 1746-1754, 2020
|Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/Programmed cell death …|
A Cortellini, M Bersanelli, D Santini, S Buti, M Tiseo, K Cannita, F Perrone, ...
European Journal of Cancer 128, 17-26, 2020
|Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab …|
A Cortellini, M Di Maio, O Nigro, A Leonetti, DL Cortinovis, JGJV Aerts, ...
Journal for immunotherapy of cancer 9 (4), 2021
|Prevalence and impact of COVID-19 sequelae on treatment and survival of patients with cancer who recovered from SARS-CoV-2 infection: evidence from the OnCovid retrospective …|
DJ Pinato, J Tabernero, M Bower, L Scotti, M Patel, E Colomba, S Dolly, ...
The Lancet Oncology 22 (12), 1669-1680, 2021
|Effect of concomitant medications with immune-modulatory properties on the outcomes of patients with advanced cancer treated with immune checkpoint inhibitors: development and …|
S Buti, M Bersanelli, F Perrone, M Tiseo, M Tucci, V Adamo, LS Stucci, ...
European Journal of Cancer 142, 18-28, 2021
|Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of≥ 50%|
A Cortellini, M Tiseo, GL Banna, F Cappuzzo, JGJV Aerts, F Barbieri, ...
Cancer Immunology, Immunotherapy 69, 2209-2221, 2020
|Subliminal Salience Search Illustrated: EEG Identity and Deception Detection on the Fringe of Awareness|
H Bowman, M Filetti, D Janssen, L Su, A Alsufyani, B Wyble
PLOS One 8 (1), e54258, 2013
|Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression≥ 50%: a multicenter study with external validation|
A Cortellini, B Ricciuti, M Tiseo, E Bria, GL Banna, JGJV Aerts, F Barbieri, ...
Journal for immunotherapy of cancer 8 (2), 2020
|Immune-related adverse events of pembrolizumab in a large real-world cohort of patients with NSCLC with a PD-L1 expression≥ 50% and their relationship with clinical outcomes|
A Cortellini, A Friedlaender, GL Banna, G Porzio, M Bersanelli, ...
Clinical lung cancer 21 (6), 498-508. e2, 2020
|Predictive biomarkers for checkpoint inhibitor-based immunotherapy: the galectin-3 signature in NSCLCs|
C Capalbo, G Scafetta, M Filetti, P Marchetti, A Bartolazzi
International journal of molecular sciences 20 (7), 1607, 2019
|Late immune-related adverse events in long-term responders to PD-1/PD-L1 checkpoint inhibitors: a multicentre study|
O Nigro, G Pinotti, F De Galitiis, FR Di Pietro, R Giusti, M Filetti, ...
European Journal of Cancer 134, 19-28, 2020
|The cost of space independence in P300-BCI spellers|
S Chennu, A Alsufyani, M Filetti, AM Owen, H Bowman
Journal of neuroengineering and rehabilitation 10, 1-13, 2013
|Countering countermeasures: Detecting identity lies by detecting conscious breakthrough|
H Bowman, M Filetti, A Alsufyani, D Janssen, L Su
PloS one 9 (3), e90595, 2014
|Clinical outcomes and toxic effects of single-agent immune checkpoint inhibitors among patients aged 80 years or older with cancer: a multicenter international cohort study|
CA Nebhan, A Cortellini, W Ma, T Ganta, H Song, F Ye, R Irlmeier, ...
JAMA oncology 7 (12), 1856-1861, 2021
|The lung immuno-oncology prognostic score (LIPS-3): a prognostic classification of patients receiving first-line pembrolizumab for PD-L1≥ 50% advanced non-small-cell lung cancer|
GL Banna, A Cortellini, DL Cortinovis, M Tiseo, J Aerts, F Barbieri, ...
ESMO open 6 (2), 100078, 2021